Peginterferon alfa-2b
Based on 1 Customer Validation
Peginterferon alfa-2b (PegIFN a-2b; Sch 54031; Sylatron; ViraferonPeg) is an immunomodulator. Peginterferon alfa-2b is a recombinant alfa-2b interferon covalently linked PEG with antiviral activity against HCV. Peginterferon alfa-2b decreases viral DNA in HIV. Peginterferon alfa-2b can be used in research of melanoma and hepatitis C.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: ≥99.0%
- CAS No.: 215647-85-1
- Masse moléculaire:31 kDa; PEG 12 kDa
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
Peginterferon alfa-2b provides benefits to individuals with cirrhosis due to chronic hepatitis C who already have portal hypertension[1].
Peginterferon alfa-2b can induce melanogenesis by upregulating melanocortin receptors on melanocytes, thereby causing the adverse reaction of tongue pigmentation[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Conjugated with pegol
The product can be reconstituted/diluted with sterile PBS or saline.
-
IFNA2 (interferon alpha 2)*b (R46,H57)24-188
Chemical Information
-
CAS No. 215647-85-1
-
Appearance Liquid
-
Masse moléculaire 31 kDa; PEG 12 kDa
-
Color Colorless to light yellow
-
SMILES
[Peginterferon alfa-2b]
-
Synonyms
PegIFN a-2b; Sch 54031; Sylatron; ViraferonPeg
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
-
Fiche technique (256 KB)
-
SDS (418 KB)
- English - EN (418 KB)
- Français - FR (418 KB)
- Deutsch - DE (418 KB)
- Norwegian - NO (418 KB)
- Español - ES (418 KB)
- Swedish - SV (418 KB)
- Italian - IT (418 KB)
- Korean - KR (418 KB)
- Portuguese - PT (418 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Références
[1]. Bruix J, et al. Maintenance therapy with peginterferon alfa-2b does not prevent hepatocellular carcinoma in cirrhotic patients with chronic hepatitis C. Gastroenterology. 2011 Jun;140(7):1990-9. [Content Brief]
[2]. Torres H A, et al. Tongue hyperpigmentation in a Caucasian patient coinfected with HIV and hepatitis C during peginterferon alfa-2b and ribavirin therapy[J]. Official journal of the American College of Gastroenterology| ACG, 2007, 102(6): 1334-1335. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Peginterferon alfa-2b Related Classifications
HY-108842 Related Classifications
Powered by Bioz
- Peginterferon alfa-2b
- 215647-85-1
- PegIFN a-2b
- Sch 54031
- Sylatron
- ViraferonPeg
- Sch54031
- Sch 54031
- Sch-54031
- HIV
- HCV
- chronic hepatitis C
- portal hypertensive events
- interferon alfa
- melanin
- hepatocellular carcinoma
- cirrhotic patients
- ribavirin
- hepatitis C virus
- melanocyte-stimulating hormone receptors
- Inhibitor
- inhibitor
- inhibit